Along years, the advent of biological therapy widely modified treatment of rheumatic diseases and other disorders. However, many agents may elicit in anti-drug antibodies (ADAbs) upon consecutive infusions, with a loss of response. For the right strategy of a personalized medicine, the therapeutic monitoring of TNF-α inhibitors and ADAbs represents an important effort in diagnostic–therapeutic pathway, to improve overall patient management and favoring an appropriate clinical approach. A raising number of diagnostic tests have been designed to elucidate the efficacy and/or safety of a specific drug or class of drugs for a targeted patient’s group. Our paper reviewed the current understanding of the immunogenicity of biological drugs employed in the treatment of inflammatory diseases underlying the laboratory role.

Grossi, V., Gulli, F., Infantino, M., Stefanile, A., Napodano, C., Benucci, M., Pocino, K., Li Gobbi, F., Damiani, A., Di Pino, A., Manfredi, M., Marino, M., Basile, V., Rapaccini, G. L., Basile, U., The Laboratory Role in anti-TNF Biological Therapy Era, <<IMMUNOLOGICAL INVESTIGATIONS>>, 2019; 2019 (12): 1-16. [doi:10.1080/08820139.2019.1637434] [http://hdl.handle.net/10807/140066]

The Laboratory Role in anti-TNF Biological Therapy Era

Annunziata Stefanile;Cecilia Napodano;Krizia Pocino;Antonella Di Pino;Mariapaola Marino;Gian Ludovico Rapaccini
Penultimo
;
Umberto Basile
Ultimo
2019

Abstract

Along years, the advent of biological therapy widely modified treatment of rheumatic diseases and other disorders. However, many agents may elicit in anti-drug antibodies (ADAbs) upon consecutive infusions, with a loss of response. For the right strategy of a personalized medicine, the therapeutic monitoring of TNF-α inhibitors and ADAbs represents an important effort in diagnostic–therapeutic pathway, to improve overall patient management and favoring an appropriate clinical approach. A raising number of diagnostic tests have been designed to elucidate the efficacy and/or safety of a specific drug or class of drugs for a targeted patient’s group. Our paper reviewed the current understanding of the immunogenicity of biological drugs employed in the treatment of inflammatory diseases underlying the laboratory role.
Inglese
Grossi, V., Gulli, F., Infantino, M., Stefanile, A., Napodano, C., Benucci, M., Pocino, K., Li Gobbi, F., Damiani, A., Di Pino, A., Manfredi, M., Marino, M., Basile, V., Rapaccini, G. L., Basile, U., The Laboratory Role in anti-TNF Biological Therapy Era, <>, 2019; 2019 (12): 1-16. [doi:10.1080/08820139.2019.1637434] [http://hdl.handle.net/10807/140066]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/140066
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 6
social impact